Tributary Capital Management LLC grew its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 23.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 496,775 shares of the medical instruments supplier’s stock after buying an additional 95,380 shares during the quarter. Tributary Capital Management LLC owned 1.34% of AngioDynamics worth $10,800,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of ANGO. Piedmont Investment Advisors LLC purchased a new stake in shares of AngioDynamics in the 2nd quarter worth $191,000. Crossmark Global Holdings Inc. purchased a new stake in shares of AngioDynamics in the 2nd quarter worth $205,000. Element Capital Management LLC purchased a new stake in shares of AngioDynamics in the 1st quarter worth $217,000. Sun Life Financial INC purchased a new stake in shares of AngioDynamics in the 2nd quarter worth $231,000. Finally, SG Americas Securities LLC purchased a new stake in shares of AngioDynamics during the 2nd quarter worth $336,000. Institutional investors and hedge funds own 97.71% of the company’s stock.
Shares of NASDAQ ANGO opened at $20.14 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.64 and a quick ratio of 1.55. The firm has a market cap of $764.33 million, a P/E ratio of 26.74 and a beta of 0.86. AngioDynamics, Inc. has a 1-year low of $15.16 and a 1-year high of $24.49.
ANGO has been the subject of a number of analyst reports. BidaskClub upgraded AngioDynamics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 22nd. Canaccord Genuity restated a “hold” rating and set a $20.00 price objective on shares of AngioDynamics in a research note on Thursday, July 12th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 11th. Finally, Raymond James cut AngioDynamics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 11th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. AngioDynamics currently has an average rating of “Buy” and an average target price of $18.44.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Featured Story: Trading Strategy Methods and Types
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.